Expert Interviews

The goal of the CARTITUDE-1 study was to evaluate the use of ciltacabtagene autoleucel (cilta-cel; JNJ-68284528) chimeric antigen receptor T-cell therapy in heavily pretreated patients with relapsed or refractory multiple myeloma.

An industry leader in psychosocial oncology detailed the importance of patient-reported outcomes to the field as a whole and emphasized a number of key details to remember when examining these end points.

Hypogammaglobulinemia was found to be nearly universal for patients with multiple myeloma during treatment with daratumumab, suggesting a role for intravenous immunoglobulin.

The study was designed to evaluate the use of ciltacabtagene autoleucel in patients with relapsed or refractory multiple myeloma in the United States.

The interview features comments on the emergence of T-cell engagers for therapy in patients with multiple myeloma made during the 2020 ASH Meeting & Exposition.

A study of the use of intravenous immunoglobulin on infections in patients with multiple myeloma receiving daratumumab suggested a role for the strategy in this patient population.

“As the number of AYA survivors continues to grow, there is a pressing need for targeted information, education, and intervention around sexual health, intimate relationships, and body image,” the Children’s Oncology Group (COG) AYA Oncology Discipline Committee wrote in a review.

The director of clinical research in the Center for Cancer Care at White Plains Hospital spoke about what she intends to evaluate for a patient population with multiple myeloma and diabetes moving forward.

The expert in urologic oncology spoke about new innovations that he believes will aid in treating patients with urologic cancers.

Short expanded on the future of acute lymphoblastic leukemia and transplantation necessity at the 2020 ASH Annual Meeting & Exposition.

An expert in multiple myeloma spoke about the most exciting research to come out of 2020 and what research he hopes to see in 2021.

An expert in the treatment of diffuse large B-cell lymphoma explained some of the exciting advances in treatment and hypothesized what comes next after the 2020 ASH Annual Meeting & Exposition.

Jeffrey Wolf, MD, explained how studies presented at the recent 2020 ASH Annual Meeting & Exposition did not report what percentage of patients achieved minimal residual disease negativity with therapy for multiple myeloma, and that the future of phase 3 trials should focus on this status in patients.

Murphy discussed the secondary end point of equivocal findings on PSMA PET/CT from the proPSMA study presented at the SUO 21st Annual Meeting.

The director of clinical research in the Center for Cancer Care at White Plains Hospital spoke about the implications of a study which evaluated the impact of diabetes in patients with multiple myeloma.

An expert in urologic oncology seeks to answer further questions regarding the use of telemedicine for this patient population.

Short described the importance of the time point of CR outcomes for patients treated as part of an ALL study presented at the 2020 American Society of Hematology Annual Meeting & Exposition.

Ghobadi expressed caution about interpreting efficacy data from a phase 1 pilot study presented at the 2020 ASH Annual Meeting.

Wolf touched on the future of MRD and the potential development of more sensitive measuring techniques for patients with multiple myeloma.